A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs DS 102 (Primary)
- Indications Alcoholic hepatitis
- Focus Therapeutic Use
- Sponsors Afimmune
- 12 Nov 2018 Planned initiation date changed from 1 Jun 2018 to 1 Nov 2018.
- 26 Feb 2018 Status changed from planning to not yet recruiting.
- 01 Aug 2017 New trial record